Updated from 3:16 p.m. EDTBuoyed by the idea that swine flu fears could at least temporarily boost sales at some firms, health care stocks were largely in the green Monday. GlaxoSmithKline ( GSK), which makes antiviral drug Relenza, was among the day's early winners. The company, which issued a press release Monday that said it had sent Mexican officials 100,000 packs of Relenza and 170,000 additional doses of its seasonal flu vaccine, is "urgently assessing" ways to increase production of Relenza. Shares of the company rose 7.6% to $31.56. Novavax ( NVAX), which owns technology for creating vaccines, rose 79.6% to $2.55.